var data={"title":"Pathogenesis of antiphospholipid syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pathogenesis of antiphospholipid syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/contributors\" class=\"contributor contributor_credentials\">Peter H Schur, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/contributors\" class=\"contributor contributor_credentials\">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/contributors\" class=\"contributor contributor_credentials\">Monica Ramirez Curtis, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 15, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antiphospholipid syndrome (APS) is defined by the presence of two major components:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence in the plasma of at least one type of autoantibody known as an antiphospholipid antibody (aPL)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The occurrence of at least one of the following clinical manifestations: venous or arterial thromboses, or pregnancy morbidity</p><p/><p>The mechanisms by which aPLs cause thrombosis are not completely understood.</p><p>APS occurs either as a primary condition or in the setting of an underlying disease, particularly systemic lupus erythematosus (SLE).</p><p>The pathogenesis of the APS will be reviewed here. The clinical manifestations, diagnosis, and treatment of the APS are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-of-antiphospholipid-syndrome\" class=\"medical medical_review\">&quot;Clinical manifestations of antiphospholipid syndrome&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-antiphospholipid-syndrome\" class=\"medical medical_review\">&quot;Diagnosis of antiphospholipid syndrome&quot;</a> and <a href=\"topic.htm?path=treatment-of-antiphospholipid-syndrome\" class=\"medical medical_review\">&quot;Treatment of antiphospholipid syndrome&quot;</a> and <a href=\"topic.htm?path=management-of-antiphospholipid-syndrome-in-pregnant-and-postpartum-women\" class=\"medical medical_review\">&quot;Management of antiphospholipid syndrome in pregnant and postpartum women&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of antiphospholipid syndrome (APS)-associated clinical manifestations appears to result from a variety of antiphospholipid antibody (aPL) effects upon pathways of coagulation, including the procoagulant actions of these antibodies upon protein C, annexin V, platelets, serum proteases, toll-like receptors, tissue factor, and via impaired fibrinolysis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/1-8\" class=\"abstract_t\">1-8</a>]. aPL may mediate effects via signaling pathways such as phosphatidyl-inositol <span class=\"nowrap\">3-kinase/AKT</span> pathway [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"topic.htm?path=antiphospholipid-syndrome-and-the-kidney#H7\" class=\"medical medical_review\">&quot;Antiphospholipid syndrome and the kidney&quot;, section on 'Renal transplantation'</a>.)</p><p>In addition to heightening the risk of vascular thrombosis, aPL increase vascular tone, thereby increasing the susceptibility to atherosclerosis, fetal loss, and neurological damage [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/10\" class=\"abstract_t\">10</a>].</p><p>The most commonly accepted explanation for the development of aPL is that they occur in susceptible individuals following incidental exposure to infectious agents or in the milieu of rheumatic diseases such as systemic lupus erythematosus (SLE). However, the conditions creating such susceptibility remain largely undefined.</p><p>Current thinking about the pathogenesis of the APS holds that once aPL are present, a &quot;second hit&quot; is required for the development of the full-blown syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/11\" class=\"abstract_t\">11</a>]. Potential candidates for the delivery of such a second hit are smoking, prolonged immobilization, pregnancy and the postpartum period, oral contraceptive use, hormone replacement therapy, malignancy, nephrotic syndrome, hypertension, and hyperlipidemia.</p><p>Clues to the pathogenesis of the APS derive from in vitro experiments and animal models, many of which suggest that antibodies to beta2-glycoprotein-I (beta2-GP-I) play an important role [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/12-37\" class=\"abstract_t\">12-37</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Clinical studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical studies in humans are consistent with findings from in vitro and animal model experiments about the importance of complement activation and antibodies to beta2-GP-I in disease pathogenesis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with primary APS had lower levels of CH50, C3 and C4 than controls; they also had increased levels of complement fragments indicative of complement activation (ie, C3a and C4a) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/38\" class=\"abstract_t\">38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When immunohistochemical analyses were performed on placentas from 47 patients with aPL and 23 healthy controls, there was evidence of increased complement deposition within the trophoblast cytoplasm, trophoblastic cell and basement membrane, and extravillous trophoblasts of placentas from aPL patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/32\" class=\"abstract_t\">32</a>]. These findings are consistent with murine studies implicating complement as a critical factor in fetal tissue injury [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/29-31\" class=\"abstract_t\">29-31</a>].</p><p/><p>However, it remains uncertain whether complement activation causes a hypercoagulable state, or, results from it.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibodies to beta2-GP-I correlate better with the development of APS than do aCL or lupus anticoagulants (LAs) alone [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/39-44\" class=\"abstract_t\">39-44</a>]. As an example, in a study of 100 patients with an LA, 12 of the 14 who developed a thromboembolic event had prolongations of their dilute Russell viper venom time (dRVVT) assay, a coagulation test that is highly sensitive for antibodies to beta2-GP-I [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/44\" class=\"abstract_t\">44</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibodies to beta2-GP-I were found in 35 of 39 lupus patients with features of APS compared with only two of 55 patients without APS [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/41\" class=\"abstract_t\">41</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with antibodies to beta2-GP-I but without either LA or aCL can display the clinical features of APS, including venous <span class=\"nowrap\">and/or</span> arterial thromboses [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/45,46\" class=\"abstract_t\">45,46</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>APS patients express greater quantities of tissue factor, the major initiator of coagulation in vivo, on the surfaces of monocytes. In one report, enhanced monocyte expression of tissue factor was observed in patients with primary APS and a history of thrombosis, but not in patients with aPL without thrombosis or in patients with thrombosis but without aPL [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/47\" class=\"abstract_t\">47</a>]. Monocytes from patients with thromboembolic phenomena also appear to over-express potentially procoagulant proteins including annexin I and II, protein disulfide isomerase, Nedd8, RhoA, and heat shock protein-60 on their surfaces; by contrast, monocytes from patients with recurrent abortions reportedly over-express fibrinogen and hemoglobin [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/48\" class=\"abstract_t\">48</a>].</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Interaction with other antibodies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>aPLs may also exert their effects through complex interactions with other antibodies. As examples, patients with APS may also have antibodies directed against <span class=\"nowrap\">heparin/heparan</span> sulfate, platelet-activating factor, tissue-type plasminogen activator, annexins (2, IV, and V), thromboplastin, oxidized low-density lipoproteins, thrombomodulin, kininogen, and coagulation factors VII, VIIa, and XII [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/10,49-64\" class=\"abstract_t\">10,49-64</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Microparticles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Microparticles are fragments of cell surface membranes that are released from apoptotic, activated, and damaged cells. The plasma concentration of microparticles that are derived from endothelial cells is increased among patients with APS when compared with people with aPL without thrombotic events and to healthy controls [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/65-67\" class=\"abstract_t\">65-67</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">GENETIC PREDISPOSITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Genetic risk factors such as concurrence of coagulation factor mutations heighten the risk of antiphospholipid antibody (aPL)-associated thrombosis. In different studies, factor V Leiden, the prothrombin gene mutation, and activated protein C resistance were associated with an increased risk of venous thromboembolism in patients with aPL [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/68,69\" class=\"abstract_t\">68,69</a>]. (See appropriate topic reviews on the different hypercoagulable states).</p><p>Several other types of studies have implicated genetic factors in the pathogenesis of the APS [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/70-77\" class=\"abstract_t\">70-77</a>].</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiphospholipid syndrome (APS) is defined by two major components:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Presence in the plasma of at least one type of autoantibody known as an antiphospholipid antibody (aPL)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The occurrence of at least one clinical feature: either venous or arterial thromboses, or pregnancy morbidity</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The pathogenesis of the APS-associated clinical manifestations appears to result from a variety of aPL effects upon pathways of coagulation, including the procoagulant actions of these antibodies upon protein C, annexin V, platelets, and fibrinolysis. (See <a href=\"#H11\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most commonly accepted explanation for the development of aPL is that they occur in susceptible individuals following incidental exposure to infectious agents. However, aside from the milieu of rheumatic diseases such as systemic lupus erythematosus (SLE), the conditions creating such susceptibility remain largely undefined.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Current thinking about the pathogenesis of the APS holds that once aPL are present, a &quot;second hit&quot; is required for the development of the full-blown syndrome.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple in vitro experiments suggest that antibodies to beta2-GP-I play an important role in the APS.</p><p/><p class=\"headingAnchor\" id=\"H445217\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Bonnie Bermas, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/1\" class=\"nounderline abstract_t\">Forastiero R, Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus 2008; 17:872.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/2\" class=\"nounderline abstract_t\">Urbanus RT, Derksen RH, de Groot PG. Platelets and the antiphospholipid syndrome. Lupus 2008; 17:888.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/3\" class=\"nounderline abstract_t\">Chen PP, Giles I. Antibodies to serine proteases in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12:45.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/4\" class=\"nounderline abstract_t\">Rand JH, Wu XX, Quinn AS, Taatjes DJ. Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 2008; 17:922.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/5\" class=\"nounderline abstract_t\">Raschi E, Borghi MO, Grossi C, et al. Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 2008; 17:937.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/6\" class=\"nounderline abstract_t\">Cockrell E, Espinola RG, McCrae KR. Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus 2008; 17:943.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/7\" class=\"nounderline abstract_t\">Kinev AV, Roubey RA. Tissue factor in the antiphospholipid syndrome. Lupus 2008; 17:952.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/8\" class=\"nounderline abstract_t\">Bu C, Gao L, Xie W, et al. beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum 2009; 60:559.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/9\" class=\"nounderline abstract_t\">Canaud G, Bienaim&eacute; F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014; 371:303.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/10\" class=\"nounderline abstract_t\">Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004; 136:393.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/11\" class=\"nounderline abstract_t\">Erkan D, Lockshin MD. What is antiphospholipid syndrome? Curr Rheumatol Rep 2004; 6:451.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/12\" class=\"nounderline abstract_t\">Merrill JT, Zhang HW, Shen C, et al. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 1999; 81:748.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/13\" class=\"nounderline abstract_t\">Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med 1996; 47:533.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/14\" class=\"nounderline abstract_t\">Male C, Mitchell L, Julian J, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97:844.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/15\" class=\"nounderline abstract_t\">Galli M, Willems GM, Rosing J, et al. Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 2005; 129:240.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/16\" class=\"nounderline abstract_t\">Hurtado V, Montes R, Gris JC, et al. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood 2004; 104:1369.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/17\" class=\"nounderline abstract_t\">Yoshida K, Arai T, Kaburaki J, et al. Restricted T-cell receptor beta-chain usage by T cells autoreactive to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Blood 2002; 99:2499.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/18\" class=\"nounderline abstract_t\">De Jong A, Ziboh V, Robbins D. Antiphospholipid antibodies and platelets. Curr Rheumatol Rep 2000; 2:238.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/19\" class=\"nounderline abstract_t\">Shi T, Giannakopoulos B, Yan X, et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54:2558.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/20\" class=\"nounderline abstract_t\">Vlachoyiannopoulos PG, Mavragani CP, Bourazopoulou E, et al. Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus. Thromb Haemost 2004; 92:1303.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/21\" class=\"nounderline abstract_t\">Yellin MJ, Brett J, Baum D, et al. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med 1995; 182:1857.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/22\" class=\"nounderline abstract_t\">Silver RK, Mullen TA, Caplan MS, et al. Inducible platelet adherence to human umbilical vein endothelium by anticardiolipin antibody-positive sera. Am J Obstet Gynecol 1995; 173:702.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/23\" class=\"nounderline abstract_t\">Nojima J, Kuratsune H, Suehisa E, et al. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004; 91:967.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/24\" class=\"nounderline abstract_t\">Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004; 50:2911.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/25\" class=\"nounderline abstract_t\">Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96:2211.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/26\" class=\"nounderline abstract_t\">Del Papa N, Guidali L, Spatola L, et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 1995; 13:179.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/27\" class=\"nounderline abstract_t\">Vega-Ostertag M, Casper K, Swerlick R, et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52:1545.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/28\" class=\"nounderline abstract_t\">Hamid C, Norgate K, D'Cruz DP, et al. Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis 2007; 66:1000.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/29\" class=\"nounderline abstract_t\">Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/30\" class=\"nounderline abstract_t\">Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 2003; 12:535.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/31\" class=\"nounderline abstract_t\">Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10:1222.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/32\" class=\"nounderline abstract_t\">Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196:167.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/33\" class=\"nounderline abstract_t\">Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A 1991; 88:3069.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/34\" class=\"nounderline abstract_t\">Bakimer R, Fishman P, Blank M, et al. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89:1558.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/35\" class=\"nounderline abstract_t\">Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109:797.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/36\" class=\"nounderline abstract_t\">Gharavi AE, Wilson W, Pierangeli S. The molecular basis of antiphospholipid syndrome. Lupus 2003; 12:579.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/37\" class=\"nounderline abstract_t\">Giles IP, Isenberg DA, Latchman DS, Rahman A. How do antiphospholipid antibodies bind beta2-glycoprotein I? Arthritis Rheum 2003; 48:2111.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/38\" class=\"nounderline abstract_t\">Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009; 68:1030.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/39\" class=\"nounderline abstract_t\">Roubey RA. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39:1444.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/40\" class=\"nounderline abstract_t\">Cabral AR, Cabiedes J, Alarc&oacute;n-Segovia D. Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol 1995; 22:1894.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/41\" class=\"nounderline abstract_t\">Cabiedes J, Cabral AR, Alarc&oacute;n-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22:1899.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/42\" class=\"nounderline abstract_t\">Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:1466.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/43\" class=\"nounderline abstract_t\">Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to beta 2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum 1996; 39:1606.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/44\" class=\"nounderline abstract_t\">Galli M, Finazzi G, Norbis F, et al. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999; 81:695.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/45\" class=\"nounderline abstract_t\">Day HM, Thiagarajan P, Ahn C, et al. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998; 25:667.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/46\" class=\"nounderline abstract_t\">Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996; 101:472.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/47\" class=\"nounderline abstract_t\">Cuadrado MJ, L&oacute;pez-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997; 40:834.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/48\" class=\"nounderline abstract_t\">L&oacute;pez-Pedrera C, Cuadrado MJ, Her&aacute;ndez V, et al. Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum 2008; 58:2835.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/49\" class=\"nounderline abstract_t\">Galli M. Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 1996; 5:388.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/50\" class=\"nounderline abstract_t\">Puurunen M, Vaarala O, Julkunen H, et al. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996; 80:16.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/51\" class=\"nounderline abstract_t\">Jones DW, MacKie IJ, Gallimore MJ, Winter M. Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol 2001; 113:550.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/52\" class=\"nounderline abstract_t\">Bidot CJ, Jy W, Horstman LL, et al. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol 2003; 120:618.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/53\" class=\"nounderline abstract_t\">Shibata S, Harpel PC, Gharavi A, et al. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994; 83:2532.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/54\" class=\"nounderline abstract_t\">Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996; 5:442.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/55\" class=\"nounderline abstract_t\">Wu R, Nityanand S, Berglund L, et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17:3159.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/56\" class=\"nounderline abstract_t\">Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 2004; 104:2783.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/57\" class=\"nounderline abstract_t\">Gromnica-Ihle E, Sch&ouml;ssler W. Antiphospholipid syndrome. Int Arch Allergy Immunol 2000; 123:67.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/58\" class=\"nounderline abstract_t\">Cesarman-Maus G, R&iacute;os-Luna NP, Deora AB, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006; 107:4375.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/59\" class=\"nounderline abstract_t\">Satoh A, Suzuki K, Takayama E, et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999; 26:1715.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/60\" class=\"nounderline abstract_t\">Song KS, Park YS, Kim HK. Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2000; 43:557.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/61\" class=\"nounderline abstract_t\">Bertolaccini ML, Sanna G, Ralhan S, et al. Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. Thromb Haemost 2003; 90:636.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/62\" class=\"nounderline abstract_t\">Mu&ntilde;oz-Rodr&iacute;guez FJ, Reverter JC, Font J, et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica 2000; 85:632.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/63\" class=\"nounderline abstract_t\">Tektonidou MG, Petrovas CA, Ioannidis JP, et al. Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. Eur J Clin Invest 2000; 30:646.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/64\" class=\"nounderline abstract_t\">Cugno M, Cabibbe M, Galli M, et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103:2121.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/65\" class=\"nounderline abstract_t\">Dignat-George F, Camoin-Jau L, Sabatier F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91:667.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/66\" class=\"nounderline abstract_t\">Ambrozic A, Bozic B, Kveder T, et al. Budding, vesiculation and permeabilization of phospholipid membranes-evidence for a feasible physiologic role of beta2-glycoprotein I and pathogenic actions of anti-beta2-glycoprotein I antibodies. Biochim Biophys Acta 2005; 1740:38.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/67\" class=\"nounderline abstract_t\">Morel O, Jesel L, Freyssinet JM, Toti F. Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis. Thromb J 2005; 3:15.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/68\" class=\"nounderline abstract_t\">Brouwer JL, Bijl M, Veeger NJ, et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104:143.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/69\" class=\"nounderline abstract_t\">Nojima J, Kuratsune H, Suehisa E, et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002; 118:577.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/70\" class=\"nounderline abstract_t\">Goldberg SN, Conti-Kelly AM, Greco TP. A family study of anticardiolipin antibodies and associated clinical conditions. Am J Med 1995; 99:473.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/71\" class=\"nounderline abstract_t\">Schur PH. Genetics of systemic lupus erythematosus. Lupus 1995; 4:425.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/72\" class=\"nounderline abstract_t\">Lundstr&ouml;m E, Gustafsson JT, J&ouml;nsen A, et al. HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2013; 72:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/73\" class=\"nounderline abstract_t\">Karassa FB, Bijl M, Davies KA, et al. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 2003; 48:1930.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/74\" class=\"nounderline abstract_t\">Jim&eacute;nez S, T&agrave;ssies D, Espinosa G, et al. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis 2008; 67:835.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/75\" class=\"nounderline abstract_t\">Hirose N, Williams R, Alberts AR, et al. A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum 1999; 42:1655.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/76\" class=\"nounderline abstract_t\">Sanchez ML, Katsumata K, Atsumi T, et al. Association of HLA-DM polymorphism with the production of antiphospholipid antibodies. Ann Rheum Dis 2004; 63:1645.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-antiphospholipid-syndrome/abstract/77\" class=\"nounderline abstract_t\">Yin H, Borghi MO, Delgado-Vega AM, et al. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 2009; 60:2468.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4676 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H25\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">PATHOGENESIS</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Clinical studies</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Interaction with other antibodies</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Microparticles</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">GENETIC PREDISPOSITION</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">SUMMARY</a></li><li><a href=\"#H445217\" id=\"outline-link-H445217\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antiphospholipid-syndrome-and-the-kidney\" class=\"medical medical_review\">Antiphospholipid syndrome and the kidney</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-antiphospholipid-syndrome\" class=\"medical medical_review\">Clinical manifestations of antiphospholipid syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-antiphospholipid-syndrome\" class=\"medical medical_review\">Diagnosis of antiphospholipid syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-antiphospholipid-syndrome-in-pregnant-and-postpartum-women\" class=\"medical medical_review\">Management of antiphospholipid syndrome in pregnant and postpartum women</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-antiphospholipid-syndrome\" class=\"medical medical_review\">Treatment of antiphospholipid syndrome</a></li></ul></div></div>","javascript":null}